BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

InterMune, Inc. 

3280 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-466-2200 Fax: 415-466-2329


SEARCH JOBS

View Clinical Trials from BioPharm Insight

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing IPF and HCV infections. The pulmonology portfolio includes Actimmune®, which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology.

For additional information about InterMune and its R&D pipeline, please visit: www.intermune.com


 Key Statistics


Email:
Ownership:

Web Site: InterMune, Inc.
Employees:
Symbol: ITMN
 




Segment
Drug Discovery





 Company News
InterMune, Inc. (ITMN) To Release Second Quarter Financial Results On August 6 7/28/2014 8:41:32 AM
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/17/2014 10:50:06 AM
InterMune, Inc. (ITMN) Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF 5/27/2014 9:20:00 AM
InterMune, Inc. (ITMN) Announces Additional Pirfenidone Data In Idiopathic Pulmonary Fibrosis 5/21/2014 9:14:49 AM
InterMune, Inc. (ITMN) Release: Phase 3 ASCEND Study Of Pirfenidone In Idiopathic Pulmonary Fibrosis Presented At American Thoracic Society And Published The New England Journal of Medicine 5/19/2014 1:13:02 PM
InterMune, Inc. (ITMN) Rises After Fatal Lung Disease Drug Slows Damage In Phase 3 Study 5/19/2014 7:51:05 AM
InterMune, Inc. (ITMN) Announces Expanded Access Program For Pirfenidone To Treat Idiopathic Pulmonary Fibrosis (IPF) In The United States 5/16/2014 9:14:56 AM
InterMune, Inc. (ITMN) Announces Upcoming Data Presentations At 2014 American Thoracic Society Meeting 5/12/2014 6:45:21 AM
InterMune, Inc. (ITMN) Reports First Quarter 2014 Financial Results, Clinical Development And Business Highlights 5/2/2014 8:40:04 AM
InterMune, Inc. (ITMN) To Release First Quarter Financial Results On May 1 4/23/2014 6:38:14 AM
12345678910...